All In Biotech

Drug Trial Radar · NCT04720157

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,144 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,144

Actual

Start

Jun 9, 2021

Primary completion

Jan 13, 2025

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
Collaborators
Alliance Foundation Trials, LLC.; RTOG Foundation, Inc.
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy (ARDT) + Androgen Deprivation Therapy (ADT). Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants were enrolled in 19 countries.

Conditions

  • Prostatic Neoplasms

Interventions

  • 177Lu-PSMA-617Drug

    administered intravenously once every 6 weeks (1 cycle) for 6 cycles

  • 68Ga-PSMA-11Drug

    Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD

  • ARDTDrug

    Administered orally on a continuous basis as per package insert and guideline

  • ADTDrug

    ADT are administered as per physician order

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression Free Survival (rPFS)Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months

Locations

164 sites in 19 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Scottsdale, Arizona

  • University of California San Diego - Moores Cancer Center

    La Jolla, California

  • VA Greater LA Healthcare System

    Los Angeles, California

  • University of California LA

    Los Angeles, California

  • St. Joseph Hospital

    Orange, California

  • Univ Cali Irvine ALS Neuromuscular

    Orange, California

  • VA Palo Alto Health Care System

    Palo Alto, California

  • Stanford University Medical Center

    Palo Alto, California

  • Sansum Clinic

    Santa Barbara, California

  • Providence Saint Johns Health Ctr

    Santa Monica, California

  • Univ Of Color Anschutz Med Center

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Hartford Hospital

    Hartford, Connecticut

  • Georgetown University-Lombardi Cancer Center

    Washington D.C., District of Columbia

  • VA Medical Center

    Washington D.C., District of Columbia

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • University Of Miami

    Miami, Florida

  • Baptist Health South

    Miami, Florida

  • Florida Cancer Affiliates

    Panama City, Florida

  • University Cancer and Blood Center LLC

    Athens, Georgia

  • The Queens Medical Centre

    Honolulu, Hawaii

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Hines VA Hospital

    Hines, Illinois

  • Parkview Research Center

    Fort Wayne, Indiana

  • Indiana University

    Indianapolis, Indiana

  • Tulane Cancer Center

    New Orleans, Louisiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Sidney Kimmel CCC At JH

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Uni Of Michigan Health System

    Ann Arbor, Michigan

  • Corewell Health William Beaum Hosp

    Royal Oak, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • University of Mississippi Med Ctr

    Jackson, Mississippi

  • St Louis University

    St Louis, Missouri

  • VA St Louis Health Care System

    St Louis, Missouri

  • Wash U School of Medicine

    St Louis, Missouri

Showing 40 of 164 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.